Home・Listă Acțiuni・Novavax Inc

Novavax Inc

Închisă

SectorSănătate

7.65 3.1

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

7.4

Maxim

7.6899999999999995

Indicatori cheie
By Trading Economics
Venit	-27M -9.5M
Vânzări	-7.6M 140M
P/E Medie Sector	3.112 64.641
EPS	-0.06
Marjă de profit	-6.803
Angajați	749
EBITDA	-29M -543K

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+45.07% upside

Dividende
By Acuity
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-89M 1.2B
Deschiderea anterioară	4.55
Închiderea anterioară	7.65

Sentimentul știrilor

By Acuity

50%

151 / 340 Clasament în Healthcare

Novavax Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 iul. 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 iul. 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 iul. 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 iul. 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 iul. 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 iul. 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 iul. 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 iul. 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 iul. 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 iul. 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Comparație

Modificare preț

Novavax Inc Așteptări

Obiectiv de preț

By TipRanks

45.07% sus

Prognoză pe 12 luni

Medie 10.75 USD 45.07%

Maxim 19 USD

Minim 7 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovavax Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Novavax Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.